apricus wealth LLC Decreases Stock Position in Abbott Laboratories (NYSE:ABT)

apricus wealth LLC cut its holdings in Abbott Laboratories (NYSE:ABT) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,895 shares of the healthcare product maker’s stock after selling 105 shares during the period. apricus wealth LLC’s holdings in Abbott Laboratories were worth $444,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Future Financial Wealth Managment LLC purchased a new position in Abbott Laboratories in the 1st quarter valued at about $39,000. Wealthcare Advisory Partners LLC lifted its holdings in Abbott Laboratories by 23.4% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 15,110 shares of the healthcare product maker’s stock valued at $1,717,000 after purchasing an additional 2,870 shares in the last quarter. Thrive Wealth Management LLC lifted its holdings in Abbott Laboratories by 9.1% in the 1st quarter. Thrive Wealth Management LLC now owns 3,487 shares of the healthcare product maker’s stock valued at $396,000 after purchasing an additional 291 shares in the last quarter. Norway Savings Bank lifted its holdings in Abbott Laboratories by 0.9% in the 1st quarter. Norway Savings Bank now owns 31,873 shares of the healthcare product maker’s stock valued at $3,623,000 after purchasing an additional 271 shares in the last quarter. Finally, Astoria Portfolio Advisors LLC. boosted its position in shares of Abbott Laboratories by 14.4% in the first quarter. Astoria Portfolio Advisors LLC. now owns 4,072 shares of the healthcare product maker’s stock worth $443,000 after acquiring an additional 514 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 0.4 %

ABT stock opened at $116.54 on Friday. Abbott Laboratories has a twelve month low of $91.64 and a twelve month high of $121.64. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $202.74 billion, a P/E ratio of 36.31, a PEG ratio of 2.74 and a beta of 0.72. The firm has a 50 day simple moving average of $114.46 and a 200-day simple moving average of $108.62.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.65% and a return on equity of 20.18%. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $10.55 billion. During the same quarter last year, the company earned $1.14 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, equities research analysts predict that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.89%. The ex-dividend date is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 68.54%.

Insiders Place Their Bets

In other news, CEO Robert B. Ford sold 141,679 shares of Abbott Laboratories stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total value of $16,492,852.39. Following the completion of the transaction, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at approximately $25,617,068.19. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ABT. Morgan Stanley raised their target price on shares of Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 17th. Barclays raised their target price on shares of Abbott Laboratories from $140.00 to $143.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. UBS Group raised their target price on shares of Abbott Laboratories from $143.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Evercore ISI raised their price target on shares of Abbott Laboratories from $120.00 to $124.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup raised their price target on shares of Abbott Laboratories from $119.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $129.67.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.